查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1997138

軟體市場作為醫療設備：依交付方式、功能、治療領域和最終用戶分類－2026年至2032年全球預測

Software as a Medical Device Market by Delivery Mode, Functionality, Therapeutic Area, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年醫療設備軟體市值為337.6億美元，預計到2026年將成長至376.6億美元，複合年成長率為11.78%，到2032年將達到736.2億美元。

主要市場統計數據
基準年 2025 337.6億美元
預計年份：2026年 376.6億美元
預測年份 2032 736.2億美元
複合年成長率 (%) 11.78%

協調監管要求、臨床檢驗和實施方法，以進行策略決策：定位現代「軟體即醫療器材 (SaMD)」生態系統。

由軟體主導的醫療設備的重新定義正在加速，不再局限於漸進式創新，而是邁向一個演算法、連接性和使用者體驗決定臨床效用和商業性差異化的時代。本執行摘要揭示了監管環境、臨床檢驗預期和企業採用模式如何相互交織，共同塑造開發者和醫療系統合作夥伴的產品策略，並整體情況了現代軟體即醫療器材（SAMD）。

監管生命週期監測、演算法演進和混合醫療保健服務模式如何重塑產品開發、檢驗和打入市場策略。

由於監管現代化、先進演算法能力和不斷演進的醫療服務模式的融合，「軟體即醫療設備」領域正經歷著變革性的變化。監管機構越來越重視對整個生命週期的監管，而非一次性核准，這促使各機構採用持續的證據生成和上市後監測策略，重點關注實際應用中的性能和安全性。

透過供應鏈重組、採購多元化和製造本地化策略，評估美國關稅變化對企業營運的多方面影響。

美國貿易政策可能引發的關稅變化，為設計、製造或採購軟體醫療產品組件的企業帶來了一系列複雜的考量。關稅壓力可能會增加感測器和連接模組等硬體組件的整體成本，進而間接推高產品研發預算，並促使企業重新思考全球籌資策略，以維持供應鏈的韌性。

將交付方式、功能特性、終端用戶環境和治療領域專業化轉化為差異化的產品、證據和行銷方法。

細分市場層面的洞察能夠揭示產品策略與交付模式、核心功能、終端用戶環境和治療領域緊密結合時所蘊含的微妙機會和執行風險。交付模式的考量至關重要，因為行動裝置解決方案通常優先考慮無縫的患者互動和簡化的監管流程，並專注於使用者體驗；而獨立系統則需要嵌入式檢驗和更長的硬體生命週期；基於網路的平台則強調可擴展的雲端架構和資料管治框架。

了解美洲、歐洲、中東和非洲以及亞太地區監管嚴格程度、支付方期望和部署規模的差異，將有助於確定區域優先事項。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的監管流程、報銷接受度和臨床部署速度都產生了顯著影響。在美洲，監管機構日益重視上市後監測和透明度，同時與支付方保持持續對話，支付方也越來越重視可驗證的結果和真實世界療效。這些因素共同推動了對強大的臨床數據包以及與主流電子健康記錄系統互通性的需求。

透過臨床證據、整合夥伴關係和平台管理建立競爭優勢，以維持長期差異化和市場滲透。

軟體即醫療醫療設備（SaaS）領域的競爭動態由平台優勢、臨床證據深度、合作夥伴生態系統和監管成熟度等因素共同塑造。主要企業憑藉全面的臨床檢驗項目、完善的上市後監測體係以及在不同患者群體中展現一致的實際療效而脫穎而出。與成熟的醫療設備製造商、雲端服務供應商和電子健康記錄供應商建立策略合作夥伴關係，能夠擴大市場覆蓋範圍並減少整合摩擦。

採取切實可行的措施，將生命週期監管規劃、架構協調、供應鏈彈性以及臨床夥伴關係策略制度化，以實現可擴展的商業化。

產業領導企業應採取有針對性的行動，加速技術推廣應用，降低商業化風險，並確保產品完整性。首先，他們需要將生命週期監管理念融入產品藍圖，投資於清晰的方法，以持續產生臨床證據、進行上市後績效監測以及演算法更新和變更管理。這將有助於減少與監管機構的摩擦，並增強臨床醫生和保險公司的信心。

透明的混合方法，結合對關鍵相關人員的訪談、監管文件的分析以及臨床證據的整合，為可操作的策略建議提供了基礎。

本分析的調查方法結合了定性訪談、監管文件審查以及對同行評審的臨床文獻的系統性整合，旨在得出可操作的見解。關鍵資訊包括與臨床實務、監管策略、產品管理和採購部門等跨職能相關人員進行結構化訪談，從而揭示實際應用中的考量因素和證據預期。

我們將建構一個統一的策略框架，整合臨床、工程和監管要求，降低實施風險，並加速臨床部署。

醫療設備軟體融合了臨床科學、嚴謹的工程技術和監管控制，其成功取決於能否同時駕馭這三個領域。有效整合以使用者為中心的設計、檢驗的臨床性能和完善的上市後監測的產品，將贏得臨床醫生的更多信任和支付方的認可，尤其是在可靠性和互通性至關重要的醫療環境中。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：醫療設備軟體市場：以交付方式分類

  • 移動基地
  • 獨立版
  • 基於網路的

第9章：醫療設備軟體市場：功能性

  • 診斷
  • 監測
  • 預防
  • 治療

第10章：醫療設備軟體市場：依治療領域分類

  • 循環系統
    • 心律不整監測
    • 血壓監測
    • 心臟衰竭管理
  • 糖尿病管理
    • 血糖監測
    • 胰島素給藥
    • 營養管理
  • 神經病學
  • 整形外科
  • 呼吸系統

第11章：醫療設備軟體市場：依最終用戶分類

  • 門診治療
  • 診所
  • 居家照護
  • 醫院

第12章：醫療設備軟體市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：醫療設備軟體市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：醫療設備軟體市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國醫療設備軟體市場

第16章：中國醫療設備軟體市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Apple Inc.
  • Arterys, Inc.
  • Dexcom, Inc.
  • Digital Diagnostics, Inc.
  • GE HealthCare Technologies Inc.
  • Johnson & Johnson
  • Koninklijke Philips NV
  • Medtronic plc
  • MindMaze SA
  • ResMed Inc.
  • Roche Diagnostics International Ltd.
  • Siemens Healthineers AG
  • Tempus Labs, Inc.
  • Viz.ai, Inc.
Product Code: MRR-8903005C4A47

The Software as a Medical Device Market was valued at USD 33.76 billion in 2025 and is projected to grow to USD 37.66 billion in 2026, with a CAGR of 11.78%, reaching USD 73.62 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 33.76 billion
Estimated Year [2026] USD 37.66 billion
Forecast Year [2032] USD 73.62 billion
CAGR (%) 11.78%

Contextualizing the modern Software as a Medical Device ecosystem by aligning regulatory expectations, clinical validation, and deployment modalities for strategic decision-making

The software-driven redefinition of medical devices has accelerated beyond incremental innovation into an era where algorithms, connectivity, and user experience determine clinical viability and commercial differentiation. This executive summary introduces the contemporary Software as a Medical Device landscape by mapping how regulatory evolution, clinical validation expectations, and enterprise adoption patterns intersect to shape product strategy for developers and health system partners alike.

The narrative that follows synthesizes cross-functional signals from regulatory guidance on software safety and real-world performance monitoring, the maturation of algorithmic verification and validation practices, and the heightened scrutiny on cybersecurity and data integrity. It situates digital delivery modalities such as mobile applications, standalone embedded systems, and web-based platforms within the practical constraints of clinical workflows and patient engagement. The introduction underscores how functional categorizations-spanning diagnostic capabilities, continuous or episodic monitoring, preventive interventions, and therapeutic controls-inform both clinical evidence demands and commercialization pathways.

Finally, this opening frames how end users from ambulatory care and clinic networks to home care settings and hospital systems evaluate safety, usability, and interoperability. It establishes the analytical foundation for subsequent sections that examine transformative shifts, tariff-driven supply chain pressures, segment-specific insights, geographic differentials, competitive dynamics, recommended actions for leaders, methodological transparency, and a concise conclusion.

How regulatory lifecycle oversight, algorithmic evolution, and hybrid care delivery models are reshaping product development, validation, and market access strategies

The Software as a Medical Device domain is experiencing transformative shifts driven by the convergence of regulatory modernization, advanced algorithmic capabilities, and changing care delivery models. Regulatory bodies are increasingly emphasizing lifecycle oversight rather than single-point approvals, prompting organizations to adopt continuous evidence-generation and post-market surveillance strategies that emphasize real-world performance and safety monitoring.

Concurrently, advances in machine learning, edge computing, and device interoperability are expanding the functional reach of software products beyond traditional diagnostics into persistent monitoring, adaptive therapeutic modulation, and proactive prevention. As developers integrate mobile-based interfaces, standalone embedded systems, and web-based solutions, product teams must reconcile user-centric design with clinical-grade reliability and traceable data provenance.

Healthcare providers are shifting care pathways to support remote and hybrid models that elevate home care and ambulatory settings, altering requirements for usability, connectivity, and clinical escalation protocols. This shift elevates the importance of validated monitoring modalities and reliable diagnostic outputs, and it fosters new reimbursement conversations tied to demonstrated outcomes. Ultimately, these forces compel manufacturers and health systems to build resilient regulatory strategies, scalable evidence infrastructures, and tighter cross-functional execution between engineering, clinical affairs, and commercial teams.

Assessing the multifaceted operational consequences of U.S. tariff shifts through supply chain realignment, sourcing diversification, and manufacturing localization strategies

The prospect of tariff changes originating from U.S. trade policy introduces a complex set of considerations for organizations that design, manufacture, or source components for software-enabled medical products. Tariff pressures can increase the landed cost of hardware elements, such as sensors and connectivity modules, which indirectly elevates product development budgets and can prompt reconsideration of global sourcing strategies to preserve supply chain resilience.

Furthermore, tariffs influence where companies choose to localize manufacturing, service provisioning, and technical support functions. In some cases, near-shoring or regional assembly can mitigate cross-border duty exposure but requires investment in local regulatory alignment, quality systems, and workforce training. These adjustments have implications for time-to-market, the structure of distribution agreements, and contractual risk allocation with suppliers and integrators.

Beyond direct component pricing, tariff dynamics can accelerate vendor consolidation as organizations seek suppliers with diversified manufacturing footprints and integrated compliance capabilities. For software-centric devices, where hardware is a critical enabler of clinical function, these sourcing decisions affect product roadmaps, clinical trial site selection due to device availability, and post-market support models. Organizations should therefore evaluate supply chain scenarios, validate alternative component qualifications, and incorporate tariff sensitivity analyses into procurement and product planning conversations.

Translating delivery modes, functional profiles, end-user environments, and therapeutic specialization into differentiated product, evidence, and go-to-market approaches

Segment-level insights reveal nuanced opportunities and execution risks when product strategy aligns tightly with delivery mode, core functionality, end-user environment, and therapeutic focus. Delivery mode considerations matter because mobile-based solutions often prioritize seamless patient interaction and lightweight regulatory pathways around user experience, whereas standalone systems demand embedded validation and longer hardware life cycles, and web-based platforms emphasize scalable cloud architectures and data governance frameworks.

Functional segmentation creates distinct evidence and deployment imperatives: diagnostic functions require rigorous clinical validation and reproducibility across populations, monitoring functions emphasize continuous data integrity and alerting accuracy, prevention-oriented software leans on behavioral science and sustained engagement mechanisms, while therapeutic software must satisfy both clinical efficacy and safety containment in active interventions. End-user context further modifies these demands as ambulatory care and clinics emphasize workflow integration and clinician decision support, home care requires simplified installation and remote support, and hospitals demand enterprise-grade interoperability and stringent cybersecurity controls.

Therapeutic area specialization drives product feature sets and validation pathways. Cardiology-focused solutions span arrhythmia monitoring, blood pressure monitoring, and heart failure management, each imposing diverse sensor fidelity, signal-processing, and clinical alerting thresholds. Diabetes management products integrate glucose monitoring, insulin dosing algorithms, and nutritional management capabilities, which necessitate tight device-to-software integration and human factors testing. Neurology, orthopedic, and respiratory applications carry unique outcome measures and clinician acceptance criteria that must be anticipated early in development.

Understanding how regulatory rigor, payer expectations, and deployment scale vary across the Americas, Europe Middle East & Africa, and Asia-Pacific to inform geographic prioritization

Regional dynamics materially affect regulatory pathways, reimbursement receptivity, and clinical adoption rhythms across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, regulatory emphasis on post-market surveillance and transparency is accompanied by payer conversations that increasingly reward demonstrable outcomes and real-world performance. This combination accelerates demand for robust clinical data packages and interoperability with predominant electronic health record systems.

Within Europe, Middle East & Africa, regulatory frameworks emphasize harmonization across jurisdictions while imposing country-level variations in procurement behavior and health technology assessment criteria. Manufacturers must balance centralized conformity routes with tailored local evidence and pricing strategies. In the Asia-Pacific region, a rapid uptake of digital health solutions is paired with a heterogeneous regulatory landscape and a strong focus on affordability and scalable deployment, which favors modular solutions and cloud-native architectures.

Each region presents distinct operational priorities: regulatory engagement and clinical partnerships in the Americas; alignment with diverse regional authorities and reimbursement pathways across Europe, Middle East & Africa; and scalable, cost-sensitive deployment models in Asia-Pacific. Strategic commercial planning should therefore incorporate regional regulatory sequencing, local clinical validation partnerships, and differentiated pricing and support models to match payer and provider expectations.

Mapping competitive advantage through clinical evidence, integration partnerships, and platform control to sustain long-term differentiation and adoption

Competitive dynamics in Software as a Medical Device are shaped by a blend of platform advantages, clinical evidence depth, partner ecosystems, and regulatory maturity. Leading companies differentiate through comprehensive clinical validation programs, robust post-market surveillance infrastructures, and the ability to demonstrate consistent real-world performance across heterogeneous patient populations. Strategic alliances with established device manufacturers, cloud service providers, and electronic health record vendors extend reach and lower integration friction.

Smaller, agile firms often compete through focused clinical niche expertise, rapid iterative development, and strong user experience design that drives adoption in ambulatory and home care settings. These firms frequently employ modular architectures that allow selective integration with hospital systems when required. Meanwhile, organizations that control end-to-end value chains-including sensor hardware, embedded firmware, and analytics platforms-gain advantages in optimizing signal fidelity and regulatory traceability.

Mergers, acquisitions, and strategic partnerships continue to concentrate capabilities around validated data assets, regulatory know-how, and distribution channels. To remain competitive, companies should prioritize cross-functional alignment between clinical research, regulatory affairs, engineering, and commercial operations, ensure transparent performance reporting, and maintain adaptive roadmaps that reflect evolving clinical standards and payer expectations.

Actionable steps to institutionalize lifecycle regulatory planning, architecture alignment, supply chain resilience, and clinical partnership strategies for scalable commercialization

Industry leaders should take targeted actions to accelerate adoption, reduce commercialization risk, and safeguard product integrity. First, embed lifecycle regulatory thinking into product roadmaps by investing in continuous clinical evidence generation, post-market performance monitoring, and a clear approach to algorithm updates and change control. This reduces friction with regulators and supports trust among clinicians and payers.

Second, align product architecture and development practices with intended delivery modes and end-user contexts so that mobile-based offerings optimize patient engagement, standalone systems prioritize embedded reliability, and web-based platforms emphasize scalable security and data governance. Simultaneously, tailor clinical evaluation strategies to functional goals; diagnostic and therapeutic products warrant rigorous controlled studies, monitoring solutions require long-term stability and alerting accuracy metrics, and preventive applications should demonstrate sustained behavioral impact.

Third, strengthen supply chain resilience through diversified sourcing, qualification of alternative components, and contingency manufacturing plans to mitigate tariff and geopolitical disruptions. Finally, pursue strategic partnerships for distribution and integration with electronic health record vendors, and prioritize clinician-facing evidence to accelerate reimbursement conversations and institutional procurement.

A transparent mixed-methods approach combining primary stakeholder interviews, regulatory document analysis, and clinical evidence synthesis to underpin practical strategic recommendations

The research methodology underpinning this analysis blends qualitative primary interviews, regulatory document review, and systematic synthesis of peer-reviewed clinical literature to produce actionable insights. Primary inputs included structured interviews with cross-functional stakeholders spanning clinical affairs, regulatory strategy, product management, and procurement functions, which illuminated real-world deployment considerations and evidence expectations.

Regulatory guidance documents, standards for software safety, and public post-market safety communications were analyzed to identify evolving compliance imperatives and reporting obligations. Clinical literature and technical validation studies were reviewed to assess evidence requirements across diagnostic, monitoring, prevention, and therapeutic functions, while case-level assessments of device integrations provided practical lessons on interoperability and user acceptance.

The methodology emphasizes transparency around inclusion criteria for interviewees and documents, and it applies conservative inference rules when extending findings across regions or therapeutic areas. Wherever possible, conclusions are grounded in published guidance or established clinical standards, and limitations are explicitly stated to help readers evaluate applicability to specific product configurations and strategic decisions.

Synthesizing clinical, engineering, and regulatory imperatives into a cohesive strategic framework that reduces execution risk and accelerates clinical adoption

Software as a Medical Device sits at the intersection of clinical science, engineering rigor, and regulatory stewardship, and success depends on the ability to navigate all three domains concurrently. Products that effectively integrate user-centered design, validated clinical performance, and robust post-market surveillance will achieve greater clinician trust and payer acceptance, especially in care settings that emphasize reliability and interoperability.

The accelerating emphasis on lifecycle oversight, algorithmic transparency, and real-world evidence rewards organizations that institutionalize continuous data collection and rapid but controlled technical iteration. At the same time, operational realities such as tariff uncertainty, component sourcing, and regional regulatory heterogeneity require pragmatic supply chain planning and region-specific commercialization strategies.

In sum, the path to sustainable impact combines disciplined evidence generation, architecture decisions that align with target delivery modes and end-user workflows, and proactive regulatory engagement. This integrated approach reduces execution risk, shortens clinical adoption cycles, and strengthens the business case for sustained reimbursement and scale.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Software as a Medical Device Market, by Delivery Mode

  • 8.1. Mobile Based
  • 8.2. Standalone
  • 8.3. Web Based

9. Software as a Medical Device Market, by Functionality

  • 9.1. Diagnostic
  • 9.2. Monitoring
  • 9.3. Prevention
  • 9.4. Therapeutic

10. Software as a Medical Device Market, by Therapeutic Area

  • 10.1. Cardiology
    • 10.1.1. Arrhythmia Monitoring
    • 10.1.2. Blood Pressure Monitoring
    • 10.1.3. Heart Failure Management
  • 10.2. Diabetes Management
    • 10.2.1. Glucose Monitoring
    • 10.2.2. Insulin Dosing
    • 10.2.3. Nutritional Management
  • 10.3. Neurology
  • 10.4. Orthopedic
  • 10.5. Respiratory

11. Software as a Medical Device Market, by End User

  • 11.1. Ambulatory Care
  • 11.2. Clinics
  • 11.3. Home Care
  • 11.4. Hospitals

12. Software as a Medical Device Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Software as a Medical Device Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Software as a Medical Device Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Software as a Medical Device Market

16. China Software as a Medical Device Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Apple Inc.
  • 17.7. Arterys, Inc.
  • 17.8. Dexcom, Inc.
  • 17.9. Digital Diagnostics, Inc.
  • 17.10. GE HealthCare Technologies Inc.
  • 17.11. Johnson & Johnson
  • 17.12. Koninklijke Philips N.V.
  • 17.13. Medtronic plc
  • 17.14. MindMaze SA
  • 17.15. ResMed Inc.
  • 17.16. Roche Diagnostics International Ltd.
  • 17.17. Siemens Healthineers AG
  • 17.18. Tempus Labs, Inc.
  • 17.19. Viz.ai, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY FUNCTIONALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY MOBILE BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY MOBILE BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY MOBILE BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY STANDALONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY STANDALONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY STANDALONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY WEB BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY WEB BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY WEB BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY PREVENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY PREVENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY PREVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY ARRHYTHMIA MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY ARRHYTHMIA MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY ARRHYTHMIA MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY BLOOD PRESSURE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY BLOOD PRESSURE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY BLOOD PRESSURE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY HEART FAILURE MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY HEART FAILURE MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY HEART FAILURE MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY GLUCOSE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY GLUCOSE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY GLUCOSE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY INSULIN DOSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY INSULIN DOSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY INSULIN DOSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY NUTRITIONAL MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY NUTRITIONAL MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY NUTRITIONAL MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. GCC SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GCC SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 141. GCC SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 142. GCC SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 143. GCC SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. GCC SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 145. GCC SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. G7 SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. G7 SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 162. G7 SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 163. G7 SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 164. G7 SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 166. G7 SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. NATO SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. NATO SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 169. NATO SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 170. NATO SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 171. NATO SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. NATO SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 173. NATO SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY FUNCTIONALITY, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA SOFTWARE AS A MEDICAL DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)